Recent clinical trials found that a modified version of the herpesvirus, along with the immunotherapy drug nivolumab, successfully shrank tumors in one-third of patients with deadly melanoma whose cancer had stropped responding to medication.

According to Everyday Health, skin cancer is the most common type of cancer in the U.S. and melanoma, although rare, causes a large majority of skin cancer deaths. Immunotherapy treatments that use the body’s own immune system to fight cancer have reduced the number of melanoma deaths over the past decade, but not everyone responds to the treatment.

Oncologist Dr. Gino In, co-author of the current study being conducted at the Keck School of Medicine at the University of Southern California, said that about half of people with this form of advanced cancer run out of treatment options.

Read more at Newsmax© 2025 Newsmax. All rights reserved.